In uncomplicated diverticular disease, treatment is aimed at relieving symptoms.
Dr Giuseppe Comparato and colleagues from Italy evaluated the efficacy of mesalazine for symptomatic relief of uncomplicated diverticular disease of the colon.
The research team enrolled 268 consecutive eligible outpatients in 4 treatment schedules in a randomized fashion.
Group 1 included 66 patients receiving rifaximin 200 mg bid.
Group 2 included 69 patients who received rifaximin 400 mg bid.
Group 3 included 67 patients receiving mesalazine 400 mg bid.
|Global Symptomatic Scores were lower with mesalazine than with rifaximin|
|Digestive Diseases and Sciences|
The team reported that 66 patients in Group 4 received mesalazine 800 mg bid.
Treatments were administered for 10 days every month for 12 months.
The research team performed clinical evaluations at admission and at 3-month intervals for 12 months.
The team considered 12 clinical variables including upper and lower abdominal pain/discomfort, tenesmus, diarrhea, abdominal tenderness, and fever.
The research team also assessed bloating, general illness, nausea, emesis, dysuria, and bleeding.
The Global Symptomatic Score was calculated using the sum of each symptom score.
The team noted that 244 patients completed the 12- month study.
There were 24 patients who were discontinued either as voluntary dropouts or because they developed side effects and/or complications.
Group 4 demonstrated a lower frequency of many symptoms after 6 and 12 months of treatment.
The mean Global Symptomatic Score was significantly lower in Group 4 after 6 and 12 months of therapy by both intention-to-treat and per-protocol analyses.
The researchers found that patients treated with mesalazine had a lower Global Symptomatic Score than subjects treated with rifaximin during the 12-month follow-up period.
Dr Comparato's team concluded, "Cyclic administration of mesalazine is effective for symptomatic relief of uncomplicated diverticular disease of the colon."
"Some symptoms showed greater improvement with mesalazine, 800 mg bid, than with the other treatment schedules."